Description of the medicine: Deoxyribonuclease (Desoxyribonucleasum)
Deoxyribonuclease is an enzyme found in the pancreas and intestinal mucosa; albumin type protein. Hydrolyzes (depolymerizes) DNA with the formation of deoxyribonucleotides.
For medical use, obtained from the pancreas of cattle. It is a lyophilized white powder, soluble in water and isotonic sodium chloride solution; pH of 0.1% aqueous solution 3, 0 - 5, 5. Aqueous solutions (and powder) are inactivated when heated above +55 'C.
Activity is determined by the formation of acid-soluble products released by the drug under certain conditions from DNA; it is expressed in units of activity (EA). 1 mg of the drug should contain at least 1700 EA.
Drugs that are similar in action to deoxyribonuclease are sold abroad under the names "Рanсreatic dornase", "Dornavac", etc.
Deoxyribonuclease has the ability to inhibit the development of herpes viruses, adenoviruses and other viruses containing DNA. The effect is associated with the depolymerization of DNA to mono- and oligonucleotides by cleavage of internucleotide bonds. Suppressing the synthesis of viral DNA, deoxyribonuclease does not damage the DNA of macroorganism cells.
Deoxyribonuclease also causes depolymerization and liquefaction of pus.
Used for herpetic keratitis and keratouveitis, adenoviral conjunctivitis and keratitis, lung abscesses, acute catarrh of the upper respiratory tract of an adenoviral nature; to reduce viscosity and improve the evacuation of sputum and pus with bronchiectasis, lung abscesses, atelectasis, pneumonia; in the preoperative and postoperative periods in patients with purulent lung diseases, pulmonary tuberculosis.
For external use, deoxyribonuclease is used in the form of a 0.2% solution (2 mg of the drug in 1 ml) in an isotonic sodium chloride solution. Solutions are prepared daily; the shelf life of the solution is 12 hours
With herpetic keratitis and keratouveitis, 0.5 ml of a sterile solution of deoxyribonuclease is administered daily under the conjunctiva of the affected eye for 2 to 4 weeks. In addition, 2 to 3 drops of a 0.2% solution are instilled into the eye 3-4 times a day. To prevent relapse, the drug is continued to be administered for 6 to 10 days after persistent clinical improvement.
To treat adenoviral keratoconjunctivitis, 1-2 drops of a 0.05% solution in distilled water are injected into the conjunctival cavity every 1, 5 - 2 hours during the day.
In acute catarrh of the upper respiratory tract of an adenoviral nature, the solution is instilled into the nose or administered as an aerosol; inhalations of 10-15 minutes are performed 2 to 3 times a day for 2 to 5 days. For each inhalation - 3 ml of a 0.2% solution.
In the case of suppurative processes in the lungs, the solution is injected into the respiratory tract in the form of an aerosol at the rate of 1 ml of the solution for 10-15 minutes.